Vitrakvi 20 mg/ml, Lösung zum Einnehmen

7680672820026 CH-67282 Lösung
Vitrakvi 20 mg/ml, Lösung zum Einnehmen
Vitrakvi 20 mg/ml, Lösung zum Einnehmen
Vitrakvi 20 mg/ml, Lösung zum Einnehmen
1 / 3
google

Article details

Package size
100
Selling units
100
Measure
ml
Galenic form
Lösung
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Detailed composition

Substance Quantity Type Category
(N/A)
20.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance WIZUS
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance AROMA
(N/A)
- Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
174.6 MG Substance HBESI
(N/A)
2.0 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HBESI

Reimbursement information

Public price
CHF 2118.35
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/06/2022

Authorization holder

Bayer (Schweiz) AG

8045 Zürich

Authorization information

Swissmedic authorization number
67282
Drug name
Vitrakvi, Lösung zum Einnehmen
Galenic form
LSOR
ATC Code
L01EX12
Authorization status
Z
Dispensing category
A
First authorization
28/05/2020
Authorization expiration date
19/02/2029
IT Number
07.16.1.
Domain
Human medicine
Field of application
Behandlung von soliden Tumoren mit NTRK (neutrophe Tyrosin-Rezeptor-Kinase)-Genfusion

Package details

Description (FR)
VITRAKVI sol 20 mg/ml 2 fl 50 ml
Description (DE)
VITRAKVI Lös 20 mg/ml 2 Fl 50 ml
Market launch
28/05/2020
Narcotic (BTM)
No

Other package sizes (1)

VITRAKVI sol 20 mg/ml (#) fl verre 100 ml
None None
GTIN: 7680672820019
Not in V1